MagForce AG (MGFRF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MagForce AG (MGFRF) trades at $0.0004 with AI Score 38/100 (Grade D). MagForce AG is a German-based medical device company specializing in nanotechnology-based cancer therapy. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for MGFRF: MGFRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MGFRF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MGFRF: 3/3 scored disciplines lean bearish. Dominant signal: Moon AI bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MagForce AG (MGFRF) Healthcare & Pipeline Overview
MagForce AG, a German nanotechnology company, focuses on cancer therapy through its NanoTherm system, which uses magnetic hyperthermia to treat brain tumors. With a presence in Germany and Poland, the company offers a comprehensive treatment approach including planning software and magnetic field generators, operating in a competitive medical device landscape.
What Is the Investment Thesis for MGFRF?
MagForce AG presents a high-risk, high-reward investment opportunity in the niche area of nanotechnology-based cancer therapy. The company's NanoTherm therapy offers a novel approach to treating brain tumors, but its financial performance is currently weak, reflected in a negative profit margin of -3004.2% and a high P/E ratio of -329.76. Growth catalysts include expanding adoption of NanoTherm in Germany and Poland, securing regulatory approvals in new markets, and demonstrating clinical efficacy through ongoing research. The company's success hinges on its ability to commercialize its technology, achieve profitability, and navigate the competitive landscape. Investors should carefully consider the company's financial position, market adoption rate, and potential regulatory hurdles.
Based on FMP financials and quantitative analysis
MGFRF Key Highlights
- MagForce AG operates in the nanotechnology-based cancer therapy field, offering NanoTherm for brain tumor treatment.
- The company's NanoTherm therapy is complemented by NanoPlan software for treatment planning and NanoActivator for magnetic field generation.
- MagForce AG's market capitalization is approximately $0.00 billion, indicating its small size within the medical device industry.
- The company's negative profit margin of -3004.2% reflects its current lack of profitability.
- MagForce AG's stock exhibits high volatility with a beta of 3.02, suggesting significant price fluctuations relative to the market.
Who Are MGFRF's Competitors?
MGFRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.16 | +1.71% | $13.7M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.08 | -0.24% | $15.4M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.22 | +2.14% | $20.9M | 73 |
| PLSM PLSM | $3.51 | -8.12% | $22.8M | 60 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
| NVCN Neovasc Inc. | $30.03 | +0.00% | $82.9M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MGFRF's Key Strengths?
- Innovative NanoTherm technology for targeted cancer therapy.
- Comprehensive treatment system including software and hardware.
- Established presence in Germany and Poland.
- Potential for expansion into new markets and applications.
What Are MGFRF's Weaknesses?
- Limited financial resources and profitability.
- Small market capitalization and low trading volume.
- Dependence on regulatory approvals for market expansion.
- Competition from established medical device companies.
What Could Drive MGFRF Stock Higher?
- Potential regulatory approvals for NanoTherm therapy in new markets.
- Continued clinical trials demonstrating the efficacy of NanoTherm.
- Strategic partnerships with hospitals and cancer centers to expand adoption.
What Are the Key Risks for MGFRF?
- Negative return on equity (-33.9%) — the business is not currently generating profit on shareholder capital.
- Regulatory hurdles and delays in obtaining approvals for NanoTherm.
- Competition from established medical device companies and alternative cancer therapies.
- Limited financial resources and profitability.
- Dependence on a single product (NanoTherm) for revenue generation.
- Negative publicity or safety concerns regarding NanoTherm therapy.
What Are the Growth Opportunities for MGFRF?
- Expansion into New Geographic Markets: MagForce AG has the opportunity to expand its operations beyond Germany and Poland into other European countries and potentially the United States. This expansion would require regulatory approvals and significant investment in marketing and sales infrastructure. The global market for cancer therapy is substantial, offering significant revenue potential if MagForce AG can successfully navigate regulatory hurdles and establish a presence in new markets. Timeline: 2-5 years.
- Development of New Applications for NanoTherm Technology: MagForce AG can explore the use of its NanoTherm technology for the treatment of other types of cancer beyond brain tumors. This would involve conducting clinical trials and obtaining regulatory approvals for new indications. Expanding the application of NanoTherm could significantly increase the company's market opportunity and revenue potential. The timeline for developing new applications is dependent on the clinical trial process and regulatory approval timelines. Timeline: 3-7 years.
- Strategic Partnerships with Hospitals and Cancer Centers: MagForce AG can form strategic partnerships with hospitals and cancer centers to promote the adoption of NanoTherm therapy. These partnerships could involve training healthcare professionals, providing technical support, and collaborating on research projects. Building strong relationships with key stakeholders in the healthcare industry is crucial for driving the commercial success of NanoTherm. Timeline: Ongoing.
- Advancements in Nanoparticle Technology: Continued research and development in nanoparticle technology could lead to improvements in the efficacy and safety of NanoTherm therapy. This could involve developing nanoparticles with enhanced targeting capabilities, improved heat generation properties, or reduced toxicity. Technological advancements could strengthen MagForce AG's competitive position and attract more patients to its therapy. Timeline: Ongoing.
- Increased Awareness and Education: MagForce AG can invest in marketing and educational initiatives to raise awareness of NanoTherm therapy among patients, physicians, and the general public. This could involve publishing scientific articles, presenting at medical conferences, and developing patient education materials. Increased awareness could drive demand for NanoTherm and accelerate its adoption in the market. Timeline: Ongoing.
What Opportunities Does MGFRF Have?
- Expansion into new geographic markets.
- Development of new applications for NanoTherm technology.
- Strategic partnerships with hospitals and cancer centers.
- Advancements in nanoparticle technology.
What Threats Does MGFRF Face?
- Regulatory hurdles and delays.
- Competition from alternative cancer therapies.
- Technological obsolescence.
- Economic downturns and healthcare spending cuts.
What Are MGFRF's Competitive Advantages?
- Proprietary NanoTherm technology protected by patents.
- Specialized expertise in nanotechnology-based cancer therapy.
- Established presence in Germany and Poland.
- Integrated treatment system including therapy, software, and hardware.
What Does MGFRF Do?
Founded in 1997 and headquartered in Berlin, Germany, MagForce AG is a medical device company operating in the niche field of nanotechnology-based cancer therapy. The company's core offering is NanoTherm, a therapy designed for the treatment of brain tumors. This innovative approach utilizes magnetic hyperthermia to selectively heat and destroy cancer cells while minimizing damage to surrounding healthy tissue. Beyond the NanoTherm therapy itself, MagForce AG provides a comprehensive treatment solution. NanoPlan software assists physicians in developing personalized treatment plans, optimizing the effectiveness of the NanoTherm therapy for each patient. The NanoActivator, a magnetic field generator, delivers the controlled magnetic field necessary to activate the nanoparticles within the tumor. MagForce AG currently operates in Germany and Poland, focusing on expanding the adoption of NanoTherm therapy within these markets. The company faces competition from established medical device companies and other emerging cancer therapy technologies. With a small team of 33 employees, MagForce AG is focused on advancing its technology and expanding its market reach within the evolving landscape of cancer treatment.
What Products and Services Does MGFRF Offer?
- Develops NanoTherm, a nanotechnology-based therapy for treating brain tumors.
- Offers NanoPlan, a software solution for treatment planning.
- Manufactures NanoActivator, a magnetic field generator used in NanoTherm therapy.
- Provides a comprehensive treatment system for magnetic hyperthermia cancer therapy.
- Focuses on targeted cancer treatment using nanotechnology.
- Operates primarily in Germany and Poland.
How Does MGFRF Make Money?
- Sells NanoTherm therapy as a treatment option for brain tumors.
- Generates revenue from the sale of NanoPlan software licenses.
- Derives income from the sale of NanoActivator magnetic field generators.
- Partners with hospitals and clinics to offer NanoTherm therapy.
What Industry Does MGFRF Operate In?
MagForce AG operates within the medical device industry, specifically targeting the cancer therapy market. The industry is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. MagForce AG's nanotechnology-based approach offers a differentiated solution, but it faces competition from established players and alternative treatment modalities. Competitors include companies like ACORQ, AHPIQ, CHCR, GDBYF, and GENN, which are developing and marketing various cancer therapies and medical devices.
Who Are MGFRF's Key Customers?
- Hospitals and clinics specializing in cancer treatment.
- Neurosurgeons and oncologists treating brain tumor patients.
- Patients diagnosed with brain tumors who are candidates for NanoTherm therapy.
- Medical centers seeking innovative cancer treatment solutions.
MagForce AG (MGFRF) Valuation Context
Relative to its peer group, MGFRF's quantitative score of 38/100 is below the peer average of 65/100.
ROE -34%Key Financial Metrics
Return on equity for MagForce AG stands at -33.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.19 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -0.3%, the inverse of the P/E and a quick read on earnings relative to price.
MGFRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- MagForce seems to be gaining traction in the European market, reflected in recent community discussions about potential expansion.
- There's a noticeable uptick in positive sentiment regarding MagForce's NanoTherm therapy, with users sharing optimistic views on its efficacy.
- Insider activity suggests confidence, with recent reports indicating increased stock ownership among key executives.
- The general market perception of MagForce appears to be shifting positively, possibly due to increased media coverage and awareness.
Bear Case
- Some community members express concerns about the scalability of MagForce's NanoTherm therapy given its specialized nature.
- There's a lingering skepticism regarding the long-term financial viability of MagForce, highlighted in discussions about profitability challenges.
- Despite recent positive sentiment, some traders are wary of potential regulatory hurdles in expanding NanoTherm therapy's availability.
- A segment of the community believes MagForce is overvalued, citing concerns about its market capitalization relative to its current revenue.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MGFRF Latest News
No recent news available for MGFRF.
MGFRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MGFRF.
Price Targets
Wall Street price target analysis for MGFRF.
MGFRF MoonshotScore
What does this score mean?
The MoonshotScore rates MGFRF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Benjamin J. Lipps
Unknown
Information on Benjamin J. Lipps's background is not available in the provided data. Without additional source material, a detailed career history, education, and previous roles cannot be accurately presented. His professional experience prior to managing MagForce AG remains unknown.
Track Record: Information on Benjamin J. Lipps's track record is not available in the provided data. Specific achievements, strategic decisions, and company milestones under his leadership cannot be accurately assessed without additional source material. His impact on MagForce AG's performance remains unknown.
MGFRF OTC Market Information
The OTC Other tier, where MagForce AG trades, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial reporting requirements, meaning they may not be subject to the same level of scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This lack of regulation can lead to increased risks for investors due to the potential for fraud and limited information availability. Companies in this tier may be distressed, early-stage ventures, or foreign companies with limited U.S. presence.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in MGFRF.
- Low trading volume can lead to price volatility and difficulty in buying or selling shares.
- The OTC Other tier carries a higher risk of fraud and manipulation compared to major exchanges.
- The company's financial stability and long-term viability may be uncertain.
- Lack of regulatory oversight increases the potential for mismanagement and inadequate corporate governance.
- Verify the company's registration and legal standing.
- Obtain and review any available financial statements, even if limited.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor before investing.
- Determine if the company has a history of regulatory issues.
- The company has been in operation since 1997.
- MagForce AG has developed a proprietary technology (NanoTherm) for cancer therapy.
- The company has a presence in Germany and Poland.
- The company's website and marketing materials appear professional.
- The company has a small team of 33 employees.
MGFRF Healthcare Stock FAQ
What does the AI Score mean for MGFRF?
MGFRF holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. MagForce AG is a German-based medical device company specializing in nanotechnology-based cancer therapy. Their core offering, NanoTherm, provides a targeted treatment for brain tumors using …
What does MagForce AG do?
MagForce AG is a German medical device company specializing in nanotechnology-based cancer therapy. Its core product, NanoTherm, is a system for treating brain tumors using magnetic hyperthermia. The system includes NanoPlan software for treatment planning and NanoActivator, a magnetic field generator. The company focuses on providing a targeted and less invasive approach to cancer treatment compared to traditional methods like chemotherapy and radiation.
What do analysts say about MGFRF stock?
There is currently no available analyst coverage or consensus on MGFRF stock. Given its OTC listing and small market capitalization, the company is not widely followed by analysts. Investors should conduct their own thorough research and due diligence before considering an investment in MGFRF. Key valuation metrics such as P/E ratio (-329.76) and profit margin (-3004.2%) indicate the company's current lack of profitability.
What are the main risks for MGFRF?
Investing in MGFRF carries significant risks due to its OTC listing, limited financial disclosure, and small market capitalization. The company's reliance on a single product (NanoTherm) makes it vulnerable to technological obsolescence and competition. Regulatory hurdles and delays in obtaining approvals for NanoTherm could also negatively impact its growth prospects. Additionally, the company's lack of profitability and limited financial resources pose a risk to its long-term viability.
What are the key factors to evaluate for MGFRF?
MagForce AG (MGFRF) holds an AI score of 38/100 (low). Not financial advice.
How frequently does MGFRF data refresh on this page?
MGFRF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MGFRF's recent stock price performance?
MagForce AG (MGFRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative NanoTherm technology for targeted cancer therapy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MGFRF overvalued or undervalued right now?
MagForce AG (MGFRF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MGFRF before investing?
Before investing in MagForce AG (MGFRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market data may be less reliable than major exchanges.
- AI analysis pending for MGFRF.